絞り込み

18456

広告

ソフトバンクが配膳ロボットを発売 2021年1月に (財経新聞)

●飲食店で配膳・運搬を担うロボットを販売 ソフトバンクG傘下のソフトバンクロボティクスは28日、飲食店での配膳・運搬を担うロボット「Servi(サーヴィ)」を販...

  1. [企業] COVID-19入院患者へのC...
  2. 新型コロナ禍での緊急事態宣言には確かな効...
  3. [企業] 若年性特発性関節炎へのPfiz...
  4. 日本の「感染者バッシング」「マスク警察」...

ニュース一覧

Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.

著者 Wang C , Tang X , Wang J , Song J , Xu Y
Otolaryngol Head Neck Surg.2017 Apr 01 ; ():194599817699402.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)
Objective This study aimed to compare survival and toxicity between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and concurrent chemoradiotherapy (CCRT) alone in elderly patients with advanced nasopharyngeal carcinoma (NPC). Study Design Propensity-matched analysis of survival and toxicity in a retrospective elderly cohort. Setting Department of Medical Oncology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, China. Subjects and Methods In total, 193 patients with stage III to IVb NPC who were treated with IC + CCRT or CCRT alone were enrolled. A cohort with suitable propensity scores was created (82 patients in the IC + CCRT group and 82 patients in the CCRT group). Survival and toxicity were compared between the 2 groups. Results For the IC + CCRT group and the CCRT group, the 5-year locoregional failure-free survival (LRFFS) rate was 80.4% and 77.2% ( P = .53), the 5-year distant failure-free survival (DFFS) rate was 80% and 76.9% ( P = .517), the 5-year overall survival (OS) rate was 71.8% and 60.5% ( P = .26), and the 5-year cancer-specific survival (CSS) rate was 75.3% and 66.7% ( P = .144), respectively. There was a significant difference in the cumulative incidence of all grade 3 to 4 toxicities between the 2 groups (29.9% vs 17.7%, P = 4.8 × 10(-6)). Conclusions IC + CCRT had a high cumulative incidence of grade 3 to 4 toxicities in elderly patients with advanced NPC, while there were no improvements in 5-year LRFFS rate, DFFS rate, OS rate, or CSS rate between patients who underwent the IC + CCRT vs CCRT alone. Concurrent chemoradiotherapy alone is still the standard of treatment.
PMID: 28418781 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード